Quanterix Corp. agreed to acquire life sciences peer Akoya Biosciences Inc. in an all-stock deal, combining two companies ...

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Learn how this client partnered with Azenta Life Sciences to integrate industry-leading sample capabilities and ...

Evercore ISI raised the firm’s price target on Azenta (AZTA) to $50 from $48 and keeps an In Line rating on the shares. In the firm’s 2025 ...

research and laboratory facilities." The School has been awarded the prestigious Athena SWAN Gold award in recognition of its work to support women in science.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Azenta AZTA shares ended the last trading session 7.2% higher at $49.65. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Following the open science principle of accessibility, “A Universe of Sound” helps members of the public who are blind or low vision experience NASA data in a new sensory way. Sighted users also enjoy ...

Sai Life Sciences IPO listing: Sai Life Sciences shares made a strong debut on Wednesday, December 18 as they listed at ₹650 on NSE, a premium of 18.4 percent over the issue price of ₹549.